QuarterHawk — Equity ResearchQuarterHawk — Equity Research

ARS Pharmaceuticals, Inc. (SPRY)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
2

Do Nothing: fundamentalScore 2 and qualitativeScore 2 both fall below the required floor of 3 (negative stockholders' equity, ~$46M quarterly burn, $25M minimum-liquidity covenant), so no bullish entry is permitted; neither entry type qualifies anyway — a pullback limit is countertrend (price 3.595 below SMA50 4.19 with MACD -0.35), and a breakout stop above the nearest settled level 3.79 gives R/R 0.48 (< 1.0).

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

ARS Pharmaceuticals, Inc. develops ARS-1, an intranasal epinephrine spray for allergic reactions, including Neffy, a low-dose version. Founded in 2015, it is based in San Diego, California.

Fundamental

weak
Fundamental2
Speculative equity

ARS Pharmaceuticals faces high risk due to negative equity, cash burn, and liquidity constraints.

Heavily cash-burning, single-product commercial biotech: neffy revenue is ramping (TTM $122.1M; product revenue +49% in the first nine months of 2026) and third-quarter costs were cut hard, but losses, negative stockholders' equity and roughly three to four quarters of burn coverage against a $25M minimum-liquidity covenant leave the equity highly speculative. High risk; watchlist until the breakeven path is demonstrated or funded.

Sentiment

weak
Sentiment2
Flat sentiment

Sentiment remains flat following a Q3 miss and broker downgrades, with no positive catalysts in sight.

The dominant driver is a bearish Q3 2026 print (announced, 2026-11-05) — EPS missed by roughly $0.06 and revenue came in below consensus, and the post-print sell-side reaction was unambiguously negative (Raymond James cut to Outperform from Strong Buy with the target trimmed to $17; Cantor Fitzgerald maintained but lowered to $20) — sitting on top of an unresolved securities class-action overhang. The trailing-14-day aggregate is flat (+0.01 across 10 scored items) and the 30-to-90-day baseline has no measured polarity (no scorable coverage; item-level tilt mixed-to-negative), so no positive delta exists; the Red-Flag Screen is clean and no cap was applied.

Technical

weak
Technical2
Bounce in downtrend

The stock shows a short-term bounce but remains in a primary downtrend.

Chart score 2. SPRY is still in a well-established primary downtrend: price 3.595 sits below SMA20 3.64, SMA50 4.19 and SMA200 7.13 (roughly -50% from the 13.15 year high), and ADX14 30.03 with price below every long moving average is a strong DOWN-trend read rather than a bullish one. The last two sessions (+12.5% on 2026-11-09, +14.1% on 2026-11-10 off the 2.44 capitulation low) are an oversold bounce, not a trend change: RSI14 has repaired from 20.68 to 47.71 and the MACD histogram has narrowed from -0.10 to -0.01, but MACD line -0.35 remains below signal -0.34 and below zero, and the bounce has only just reached the SMA20 from underneath. What keeps this from a 1 is that the short-term stack has been reclaimed (EMA9 3.26, WMA9 3.11, DEMA14 3.04, TEMA14 3.02 all below price) and today's VWAP 3.43 sits under the tape — so the read is 'bounce-only inside a broken trend', which maps to 2, not 3. The tradable verdict is Do Nothing regardless, because fundamentalScore 2 and qualitativeScore 2 both fail the ≥3 override floor.

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.